Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
BUSINESS
Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan
Chugai Pharmaceutical said on July 4 that it has launched Hemlibra (emicizumab) in Taiwan for the routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.The drug has been previously available on…
To read the full story
Related Article
- Hemlibra Now Available in Taiwan
November 5, 2019
- Taiwan Expands Hemlibra Label into Non-VIII Inhibitor Carriers
October 31, 2019
- Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai
December 5, 2018
BUSINESS
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…